公开(公告)号：US20230365571A1

公开(公告)日：2023-11-16

申请号：US18044455

申请日：2021-09-15

Applicant: Novartis AG

Inventor： Trixi Brandl ,  Claus Ehrhardt ,  Robert Epple ,  Christian Markert ,  Pascal Rigollier ,  Juraj Velcicky

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods of using such inhibitors and compositions.

公开(公告)号：US20240199593A1

公开(公告)日：2024-06-20

申请号：US18426461

申请日：2024-01-30

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a crystalline form of (S)-2-amino-3-(3-(4-((3-fluoro-5-(1H-pyrazol-5-yl)pyridin-2-yl)oxy)phenyl)-1H-pyrazol-1-yl)propan-1-ol, in its free form;

a method for manufacturing said crystalline form, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11932630B2

公开(公告)日：2024-03-19

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian Xie

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof,




a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220348566A1

公开(公告)日：2022-11-03

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K45/06 ,  A61K31/4245 ,  A61K31/4439 ,  C07D413/14 ,  C07D471/04 ,  A61K31/436 ,  C07D401/14 ,  C07D401/12 ,  C07D257/04 ,  A61K31/41

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20140378474A1

公开(公告)日：2014-12-25

申请号：US14371457

申请日：2013-01-25

Applicant: NOVARTIS AG

Inventor： Stefanie Flohr ,  Christian Markert ,  Kenji Namoto ,  Bernard Pirard

IPC: C07D471/04 ,  C07D401/14 ,  A61K31/4155 ,  C07D403/10 ,  C07D231/14 ,  C07D413/14 ,  A61K31/497 ,  C07D401/06 ,  A61K31/4439 ,  C07D403/14 ,  A61K31/422 ,  A61K31/4709 ,  C07D403/12

CPC classification number: C07D471/04 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  C07D231/14 ,  C07D401/06 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D413/14

Abstract: The invention relates to a compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

Abstract translation: 本发明涉及式（I）化合物，其中取代基如说明书中所定义; 以游离形式或盐形式; 作为其制备，用作药物和包含它的药物。

公开(公告)号：US11453651B2

公开(公告)日：2022-09-27

申请号：US15895224

申请日：2018-02-13

Applicant: NOVARTIS AG

Inventor： Birgit Bollbuck ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn

IPC: A61K31/41 ,  A61K31/415 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  C07D231/12 ,  C07D271/10 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D257/04 ,  A61K45/06 ,  A61K31/4439

Abstract: The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.